Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral reboundsActivity shown in ...
Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 ...
Traws Pharma (TRAW) announced that interim data with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, ...
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
Scientists discover novel series of SARS-CoV-2 mpro inhibitors for potential new COVID-19 treatments
New research has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 treatments that, according to preclinical testing, effectively inhibits COVID-19 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results